Galmed Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Galmed Pharmaceuticals disminuyan en un 26.1% al año. Se prevé que el BPA aumente en un 10.5% al año.

Información clave

-26.1%

Tasa de crecimiento de los beneficios

10.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.7%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	21 Nov 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

May 16

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Oct 02

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

May 20

Galmed gets greenlight for late-stage Aramchol NASH trial in China

May 03

What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

Feb 04

We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Dec 06

Galmed EPS misses by $0.02

Nov 12

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:GLMD - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-17	N/A	N/A	1
12/31/2025	N/A	-14	N/A	N/A	1
12/31/2024	N/A	-11	N/A	N/A	1
12/31/2023	N/A	-7	-6	-6	N/A
9/30/2023	N/A	-8	-9	-9	N/A
6/30/2023	N/A	-11	-10	-10	N/A
3/31/2023	N/A	-14	-15	-15	N/A
12/31/2022	N/A	-18	-19	-19	N/A
9/30/2022	N/A	-23	-21	-21	N/A
6/30/2022	N/A	-25	-27	-27	N/A
3/31/2022	N/A	-30	-29	-29	N/A
12/31/2021	N/A	-32	-33	-33	N/A
9/30/2021	N/A	-35	-34	-34	N/A
6/30/2021	N/A	-34	-30	-30	N/A
3/31/2021	N/A	-32	-29	-29	N/A
12/31/2020	N/A	-29	-26	-26	N/A
9/30/2020	N/A	-27	-23	-23	N/A
6/30/2020	N/A	-24	-21	-21	N/A
3/31/2020	N/A	-23	-18	-18	N/A
12/31/2019	N/A	-20	-15	-15	N/A
9/30/2019	N/A	-16	-13	-13	N/A
6/30/2019	2	-12	-11	-11	N/A
3/31/2019	2	-11	-9	-9	N/A
12/31/2018	2	-10	-9	-9	N/A
9/30/2018	2	-10	-9	-9	N/A
6/30/2018	1	-12	-10	-10	N/A
3/31/2018	1	-12	-12	-12	N/A
12/31/2017	1	-12	-12	-12	N/A
9/30/2017	1	-13	N/A	-12	N/A
6/30/2017	1	-15	N/A	-13	N/A
3/31/2017	1	-16	N/A	-13	N/A
12/31/2016	0	-17	N/A	-12	N/A
9/30/2016	0	-15	N/A	-12	N/A
6/30/2016	N/A	-14	N/A	-11	N/A
3/31/2016	N/A	-12	N/A	-9	N/A
12/31/2015	N/A	-11	N/A	-8	N/A
9/30/2015	N/A	-9	N/A	-9	N/A
6/30/2015	N/A	-10	N/A	-9	N/A
3/31/2015	N/A	-9	N/A	-9	N/A
12/31/2014	N/A	-9	N/A	-9	N/A
9/30/2014	N/A	-22	N/A	-8	N/A
6/30/2014	N/A	-20	N/A	-6	N/A
3/31/2014	N/A	-19	N/A	-4	N/A
12/31/2013	N/A	-17	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que GLMD siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que GLMD siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que GLMD siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de GLMD crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: Se prevé que GLMD no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de GLMD se prevé que sea elevada dentro de 3 años.

Galmed Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$1.00

Price target decreased to US$9.25

Price target increased to US$17.00

Price target decreased to US$15.80

Forecast to breakeven in 2025

Price target decreased to US$16.40

Recent updates

Insufficient new directors

New major risk - Shareholder dilution

New major risk - Share price stability

Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Pharmaceuticals Ltd., Annual General Meeting, Sep 20, 2023

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Galmed Pharmaceuticals Ltd. Announces Issuance of New Composition of Matter Patent for Aramchol Meglumine Salt

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Galmed Pharmaceuticals Ltd. Reports Results from the Open-Label Part of the Armor Study Showing Improvements in Histology, Imaging, and Biomarkers with Aramchol

Galmed Pharmaceuticals Ltd. Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Price target decreased to US$1.00

Galmed GAAP EPS of -$0.15 beats by $0.09

Galmed Pharmaceuticals Ltd. Reports Significant Anti-Fibrotic Effects of Aramchol in A Lung Fibrosis Model

Galmed Pharmaceuticals Ltd., Annual General Meeting, Jun 29, 2022

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Price target decreased to US$9.25

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

Galmed Pharmaceuticals Ltd. Announces Executive Changes

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Galmed Pharmaceuticals Ltd. Announces Results of Phase 1 Clinical Trial of Amilo-5MER

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Price target increased to US$17.00

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

Price target decreased to US$15.80

Forecast to breakeven in 2025

Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of Nash & Fibrosis in the Global Phase 3 Armor Registrational Study

Galmed gets greenlight for late-stage Aramchol NASH trial in China

Price target decreased to US$16.40

Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER

Galmed Pharmaceuticals Ltd. to Report Q4, 2020 Results on Mar 18, 2021

Galmed Pharmaceuticals Ltd. has completed a Follow-on Equity Offering in the amount of $10 million.

New 90-day high: US$4.80

What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

Price target lowered to US$17.80

Galmed to Add Open Label Part to ARMOR Study

We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Price target lowered to US$19.60

Galmed EPS misses by $0.02

Galmed Pharmaceuticals Ltd. and MyBiotics Pharma Ltd. to Collaborate in Development of Bespoke Microbiome Signature for Aramchol

New 90-day low: US$3.06

Galmed Pharmaceuticals Ltd. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: US$3.35

New 90-day low: US$3.80

Gannex Pharma Co., Ltd. and Galmed Pharmaceuticals Ltd. Enters into a Research Agreement Aiming at Combination Therapy of ASC41 and Aramchol for the Treatment of Non-Alcoholic Steatohepatitis

New 90-day low - US$4.25

New 90-day low - US$4.46

Galmed Pharmaceuticals Ltd. to Report Q2, 2020 Results on Aug 06, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento